BIRAC: India’s Most Structured Biotech Funding Ladder

If you are building a biotech startup in India and you have not explored BIRAC, you are trying to cross an ocean without knowing there is a bridge.

Biotech is the hardest category to build in. Development timelines stretch three to seven years. Regulatory approvals take years after the product works. Capital burns at every stage — from lab experiments to preclinical testing to manufacturing scale-up. Failure rates exceed 90% before a product reaches market. And generic startup accelerators and seed funds rarely understand the difference between a TRL 3 prototype and a TRL 7 validated system.

That is exactly why BIRAC exists — and why it is arguably the most important funding institution most Indian biotech founders are not using properly.

Since its inception, BIRAC has facilitated more than ₹4,200 crore in funding to over 15 lakh startups, entrepreneurs, companies, and innovators, creating one of the world’s largest publicly supported biotech innovation networks.

Over the past decade, BIRAC has delivered over 900 products to market, established more than 100 national and international partnerships, built a mentor pool exceeding 10,000 individuals. Through the BioNEST programme, BIRAC supports 100 bio-incubators with more than 10.45 lakh square feet of space, offering startups access to laboratories, pilot facilities, instrumentation, regulatory guidance, and business assistance.

And the ecosystem it operates in is enormous and growing fast. India’s bioeconomy reached a record $195.3 billion in 2025, now contributing nearly 5% to the national GDP. India now boasts 11,855 biotech startups, with 1,780 new entries in 2025 alone — increasingly from Tier 2 and 3 cities.

Here is how the BIRAC funding ladder works — scheme by scheme — and how to climb it.

The BIG Grant: ₹50 lakh to go from idea to proof of concept

Biotechnology Ignition Grant (BIG) is the flagship programme of BIRAC which supports young startups. BIG provides early-stage funding support of ₹50 lakhs as grant-in-aid for a period of 18 months to translate innovative ideas into Proof of Concept.

BIG is the largest early-stage biotech funding program in India managed by 8 BIG partners across the nation. The scope spans diverse life sciences fields such as Healthcare (encompassing Medical devices, Drugs and Drug Delivery, Biosimilars, Diagnostics), Industrial Biotechnology, Clean Energy, Digital Solutions, Agriculture, and allied areas.

This is where most biotech founders should enter BIRAC’s system. The ₹50 lakh grant covers R&D expenses, specialised equipment, consumables, manpower, IP filing, and early regulatory preparation. It is non-dilutive — pure grant-in-aid with no equity taken.

The BIG Scheme is currently managed through 8 BIG Partners across the country who work with the Ignition grantees to provide mentoring, monitoring, networking and other business development related activities.

Key partners include IKP Knowledge Park (Hyderabad), C-CAMP (Bangalore), KIIT-TBI (Bhubaneswar), and five more. Each partner provides not just the grant money but lab access, mentorship, IP guidance, and connections to follow-on funding.

SBIRI: early-stage product development for small companies

The Small Business Innovation Research Initiative (SBIRI) was launched in 2005 to boost Public-Private-Partnership efforts in the country. SBIRI was the first of its kind, early stage, innovation focused PPP initiative in the area of Biotechnology.

SBIRI has consistently prioritised early stage funding for high risk innovative research in small and medium companies led by innovators with science backgrounds to get them involved in development of products and processes which have high societal relevance.

SBIRI sits between BIG (idea-to-PoC) and BIPP (advanced scale-up). If you have completed a BIG grant and have a validated proof of concept, SBIRI funds the next phase — turning that PoC into a product through development, testing, and initial validation work.

There are two calls for proposals in a year. Minimum 51% of the shares of the Company should be held by Indian Citizens.

BIPP: multi-crore funding for breakthrough technologies

The Biotechnology Industry Partnership Programme was launched on 5th December, 2008. BIPP is a government partnership with Industries for support on a cost sharing basis for path-breaking research in frontier futuristic technology areas having major economic potential.

BIPP is an Advanced Technology Scheme only for high risk, transformational technology and process development. It is for high risk futuristic technologies and mainly for viability gap funding. The uniqueness is that it is for “breakthrough research” which enables product and process development and is patentable, with IP ownership rights resting with industry.

The proposals spanning across the spectrum of pre-proof-of-concept to validation of established technologies are considered for support in the form of grant and/or loan. BIPP supports large, medium, small scale companies as well as startups on cost sharing basis, covering high risk discovery-linked innovation, accelerated technology development, evaluation and validation of biotech products, and infrastructure or facility set up.

BIPP is where the serious capital flows — projects are typically structured at multi-crore scale, with varying models of grants, loans, or grant-plus-loan available. This is the scheme for founders who need GMP scale-up, multi-centre clinical trials, pilot manufacturing, or advanced bio-manufacturing that individual grants cannot cover.

SPARSH: social innovation for affordable health solutions

SPARSH is strategically designed to leverage biotechnological interventions for addressing critical societal issues. The core premise revolves around nurturing a cadre of accomplished “Social Innovators” within the biotech domain, equipped to adeptly identify community needs and gaps, subsequently formulating innovative product developments or services to bridge these disparities.

SPARSH provides a comprehensive approach, encompassing immersive experiences in clinical and rural settings, complemented by essential funding assistance through mini kick-start grants. These strategic provisions empower nascent social innovators to manifest tangible prototypes with far-reaching impact.

If your biotech startup addresses an affordable health challenge — diagnostics for rural settings, low-cost medical devices, nutrition solutions, waste-to-value technologies — SPARSH provides both the immersion experience to validate your problem understanding and the funding to build the solution. Past calls have covered themes including soil and plant health, human health, waste to value, healthy mother healthy child, and ageing and health.

PACE: converting academic research into commercial enterprises

BIRAC’s comprehensive range includes PACE supporting academic research to enterprise transition.

PACE — Promoting Academic Research Conversion to Enterprise — bridges the gap between university labs and market-ready products. It has two components: AIR (where academia develops proof-of-concept independently) and CRS (where a mandatory industry partner validates and co-develops the academic IP).

For researcher-founders or academic spin-offs, PACE is the natural entry point. It forces structured industry engagement from the start — which dramatically improves the commercial viability of academic IP. If you are a professor with a breakthrough finding, or a PhD student with a patentable process, PACE converts your research into something an investor can evaluate and a market can buy.

The equity ladder: SEED Fund, LEAP Fund, AcE Fund, and BioAngels

Beyond grants, BIRAC operates a parallel equity ladder for startups that have moved past the grant stage and need growth capital.

The power of BIRAC’s system is that the grant ladder and the equity ladder work together. You enter through BIG or SPARSH (grants). You validate through SBIRI or PACE (grants plus industry engagement). And when you need growth capital, the SEED Fund, LEAP Fund, and AcE Fund provide equity investment through the same incubator network that has been supporting you all along.

The brand-new ₹2,000 crore RDI Fund — the 2026 game-changer

This is the development that changes the scale of what BIRAC can offer — and most founders have not noticed it yet.

Union Minister Dr Jitendra Singh announced the first national call for the BIRAC–RDI Fund under the government’s ₹1 lakh crore Research, Development and Innovation (RDI) initiative.

BIRAC has been appointed as a second-level fund manager under the RDI framework to deploy ₹2,000 crore over up to five years, with potential for further enhancement. This funding supports high-risk, high-impact biotech ventures from translational research to growth-stage companies through grants, equity, quasi-equity, and long-term debt.

The fund will provide support for technology across Technology Readiness Level 4 to TRL 9 using a combination of equity, convertible debt instruments and long-term loans.

The first national call is now open at biracrdiif.org. This is live — not a future announcement. Startups, SMEs, and industry partners can submit proposals now.

The RDI Fund fills the biggest gap in BIRAC’s previous system: the bridge from validated technology to industrial-scale production. BIG takes you to PoC. SBIRI takes you to product. BIPP takes you to advanced development. The RDI Fund takes you from advanced development all the way to commercial scale — with ₹2,000 crore backing it.

The 100-incubator BioNEST network — your physical infrastructure

BIRAC’s funding schemes do not operate in isolation. They are delivered through a nationwide incubation network that provides the physical infrastructure biotech startups need.

Over the past decade, BIRAC has built a robust innovation ecosystem, establishing more than 100 bio-incubation centres and creating over 10 lakh square feet of incubation space.

BioNEST incubators provide shared laboratories, pilot facilities, instrumentation, regulatory guidance, and business assistance. For biotech founders, this infrastructure is critical — you cannot run experiments, test formulations, or validate medical devices without specialised lab equipment. Building your own lab costs crores. Accessing a BioNEST facility costs a fraction of that.

The eight BIG Partner Incubators — IKP Knowledge Park, C-CAMP, KIIT-TBI, CMIE-AIIMS, and others — are the primary entry points. But the broader BioNEST network of 100-plus incubators spans the country, ensuring that biotech founders in Hyderabad, Bangalore, Pune, Delhi, Bhubaneswar, and beyond all have local access.

The bigger picture: India’s $195 billion bioeconomy

The reason BIRAC matters now more than at any point in its 14-year history is the macro context.

Dr Jitendra Singh said: “Our bioeconomy has surged from $10 billion in 2014 to $165.7 billion in 2024, and its continued momentum, growing to $195.3 billion in 2025, reflecting an 18% year-on-year increase.”

India’s biotech startup base expanded from around 50 companies in 2014 to over 11,000 in 2026. The ambition is bold: to grow India’s bioeconomy to $300 billion by 2030 and $1 trillion by 2047.

The BioE3 Policy — Biotechnology for Economy, Environment, and Employment — is creating shared pilot-scale manufacturing infrastructure for startups, reducing capital costs and time-to-market. Bio-AI hubs are being established under joint DBT-BIRAC calls. And the ₹1 lakh crore national RDI initiative, with BIRAC managing ₹2,000 crore, provides the largest-ever committed capital for biotech translation in India.

For biotech founders, this means the ecosystem is maturing faster than at any previous point. The funding is larger. The infrastructure is deeper. The regulatory pathways are clearer. And the market demand — driven by India’s healthcare needs, agricultural challenges, and climate goals — is enormous.

Who should apply to BIRAC — and who should not

BIRAC is not for pure software companies, generic e-commerce, or non-biotech service businesses. The schemes are specifically designed for innovation rooted in biology, life sciences, and biotechnology. If your product does not have a biological or biotechnological core, BIRAC’s schemes will not apply — but DPIIT’s broader startup schemes and state-level programmes will.

How to sequence the BIRAC ladder

The founders who extract maximum value from BIRAC treat the schemes as a progression — not isolated applications. Here is the optimal sequence.

BIRAC MD Dr Jitendra Kumar said: “BIRAC’s mission has always been to de-risk innovation for entrepreneurs, whether first-time founders, faculty-led startups, or MSMEs pursuing deep tech solutions. What sets our model apart is the seamless integration of funding with incubation, regulatory guidance, IP support, and market linkages, enabling early-stage ideas to evolve into validated, investible, and scalable ventures.”

Your action plan — step by step